Tom C. Freeman

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Multiomic characterisation of the clinical efficacy of guselkumab induction therapy in ulcerative colitis

  BMJ Open Gastroenterology · 2026-03-01

• Serum protein profiles differ with adalimumab and ustekinumab treatment in moderately to severely active Crohn’s disease

  Journal of Crohn s and Colitis · 2025-11-01

• Revisiter les principes d’Ian McWhinney à l’ère de la santé numérique

  Canadian Family Physician · 2025-09-01

• Revisiting Ian McWhinney’s principles in the digital health age

  Canadian Family Physician · 2025-09-01

• 0072 Single-cell transcriptome reveals keratinocyte subclusters that contribute to altered differentiation and inflammatory responses in atopic dermatitis

  Journal of Investigative Dermatology · 2025-07-21

• Metabolic gene expression differences in emaciated and moderately conditioned horses: RNA-seq analysis of postmortem skeletal muscle

  Journal of Equine Veterinary Science · 2025-05-01

• Su1980: GUSELKUMAB MAINTENANCE THERAPY MEDIATES FURTHER IMPROVEMENTS IN INTESTINAL IMMUNE HOMEOSTASIS AND MUCOSAL HEALING IN PATIENTS WITH ULCERATIVE COLITIS

  Gastroenterology · 2025-05-01

• Su1979: GUSELKUMAB INDUCTION THERAPY RESULTS IN MOLECULAR RESOLUTION OF INFLAMMATION IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

  Gastroenterology · 2025-05-01

• Su1966: CHARACTERIZATION OF SERUM INFLAMMATORY PROTEINS IN RESPONSE TO GUSELKUMAB OR USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: ANALYSIS OF THE PHASE 3 GALAXI 2 AND 3 STUDIES

  Gastroenterology · 2025-05-01

• Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling

  Frontiers in Immunology · 2025-03-12 · 27 citations

• Mitochondrial dysfunction and mitophagy blockade contribute to renal osteodystrophy in chronic kidney disease-mineral bone disorder

  Kidney International · 2025-02-06 · 17 citations

• Defining a Threshold for Higher Potency Cannabis Products in Legal MarketsPreprint

  SSRN Electronic Journal · 2025-01-01

• P0061 Guselkumab induction therapy results in molecular resolution of inflammation in moderately to severely active Ulcerative Colitis: results from the Phase 3 QUASAR induction study

  Journal of Crohn s and Colitis · 2025-01-01 · 1 citations

• DOP069 Guselkumab maintenance therapy mediates further improvements in intestinal immune homeostasis and mucosal healing in patients with ulcerative colitis

  Journal of Crohn s and Colitis · 2025-01-01 · 1 citations

• 024 Cellular and molecular heterogeneity in Hidradenitis Suppurativa

  Journal of Investigative Dermatology · 2024-11-20

• S1181 Guselkumab Decreases Key Cellular Inflammatory Processes Across Ileum and Colon Tissue in Crohn’s Disease

  The American Journal of Gastroenterology · 2024-10-01

• 94P Clinical utility of long read sequencing for comprehensive analysis of cancer patient genomes

  ESMO Open · 2024-10-01

• S1241 Guselkumab Binding to CD64+ IL-23–Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling

  The American Journal of Gastroenterology · 2024-10-01 · 2 citations

• Guselkumab and golimumab combination induction therapy in ulcerative colitis results in early local tissue healing that is sustained through guselkumab maintenance therapy

  Zeitschrift für Gastroenterologie · 2024-09-01

• 475P Optimising genomic testing for patients with central nervous system (CNS) tumours using oxford nanopore technology

  Annals of Oncology · 2024-09-01